Xcopri and Banzel drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Xcopri (cenobamate) and Banzel (rufinamide). Common drug interactions include hypersomnia among females and decreased appetite among males.

The phase IV clinical study analyzes what interactions people have when they take Xcopri and Banzel. It is created by eHealthMe based on reports of 45 people who take the same drugs from the FDA, and is updated regularly.

What is Xcopri?

Xcopri has active ingredients of cenobamate. eHealthMe is studying from 4,142 Xcopri users. Check the latest studies of Xcopri.

What is Banzel?

Banzel has active ingredients of rufinamide. It is often used in epilepsy. eHealthMe is studying from 1,590 Banzel users. Check the latest studies of Banzel.

On Jul, 23, 2026

45 people who take Xcopri and Banzel together, and have interactions are studied.

What are the common drug interactions of Xcopri and Banzel, by gender? *:

female:

Hypersomnia (excessive daytime sleepiness (eds))
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Abdominal discomfort
Diarrhoea
Nausea (feeling of having an urge to vomit)
Dysphagia (a condition in which swallowing is difficult or painful)
Fatigue (feeling of tiredness)
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Pneumonia bacterial (pneumonia associated with bacterial infection)
Adverse drug reaction

male:

Decreased appetite
Dizziness
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Acute respiratory failure
Intentional self-injury
Mental disorder (a psychological term for a mental or behavioural pattern or anomaly that causes distress or disability)
Nasopharyngitis (inflammation of the nasopharynx)
Psychotic disorder
Restlessness (not able to rest)
Salivary hypersecretion (excess saliva secretion)

What are the common drug interactions of Xcopri and Banzel, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Hypersomnia (excessive daytime sleepiness (eds))
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Abdominal discomfort
Diarrhoea
Nausea (feeling of having an urge to vomit)
Adverse drug reaction
Hypophagia (reduced food intake)

20-29:

Decreased appetite
Dizziness
Restlessness (not able to rest)
Salivary hypersecretion (excess saliva secretion)
Sleep disorder
Tricuspid valve incompetence (inefficient heart valve)
Weight decreased
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Acute respiratory failure
Cardiac valve disease (heart valve disease)

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 17 people, 37.78%
Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 9 people, 20.00%
Hypersensitivity: 6 people, 13.33%
Constipation: 6 people, 13.33%
Pain: 5 people, 11.11%
Diarrhea: 4 people, 8.89%
Skin Irritation: 3 people, 6.67%
Nosebleed (bleeding from nose): 3 people, 6.67%
Nausea (feeling of having an urge to vomit): 3 people, 6.67%
Itching: 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Xcopri and Banzel?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously